Milestones Over Sales: The Sanofi Partnership Now Drives Novavax's Outlook

Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...
Reuters

Novavax banks on vaccine supply partnerships to boost 2025 revenue

Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of ...
Nasdaq

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights ...
Benzinga.com

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...
Hosted on MSN

Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the ...
Lincoln Journal Star

Forget Merck: Novavax, Inc. Is a Better Vaccine Stock

That might sound crazy. After all, Novavax is tiny and unproven. It's losing millions of dollars every quarter. Meanwhile, Merck is an established big pharma company that makes more money from just ...
Reuters

Novavax lays out specific minority targets for U.S. COVID-19 vaccine trial

CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...